2022-05-05| Special

The FDA Issued its First Formal Warning to Companies Selling Delta-8 THC Products

by Reed Slater
Share To

The United States Food and Drug Administration announced on May 4 that it had sent warning letters to five American companies illegally selling cannabidiol (CBD) and Delta-8 THC products that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FDA focused mainly on the marketing and distribution of Delta-8 THC, stating that there are currently no FDA-approved drugs containing the compound. 


Related Article: Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies


Beginning a Crackdown on Delta-8 Commercialization


The FDA has issued warning letters to many companies in the last several years regarding CBD commercialization. Still, the FDA’s most recent warning to five companies is the first time it has issued warnings regarding Delta-8. The FDA mentioned in yesterday’s warning that one of the concerns is the illegal marketing of Delta-8 for medicinal uses, despite not being FDA approved.

GO Prime with only $1.49 now

OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
First-Ever Insect Brain Neuron Map Completed
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
Scroll to Top